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metabolic abnormalities, such as dyslipidemia, hyperglyce-
mia, and hypertension (4,5); however, the incidence of
obesity-related metabolic disturbances varies widely among
obese individuals (6,7). Indeed, a subset of obese indivi-
duals without obesity-related metabolic abnormalities (7,8),See page 2687referred to as metabolically-healthy obese (MHO), are
relatively insulin sensitive (9). Whether MHO is associated
with excess risk of CVD is controversial. MHO individuals
had similar risk for cardiovascular events as metabolically-
healthy normal-weight subjects in some studies (5,10,11)
but had increased risk in others (4,12). Importantly, a sub-
stantial fraction of MHO individuals develop adverse
metabolic changes associated with obesity over time (13,14).
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2680Coronary artery calcium
(CAC) scoring with computed
tomography (CT) is a useful
method to identify subclinical
atherosclerosis (15). CAC scores
reﬂect the long-term impact of
elevated CVD risk factors and
independently predict future risk
of CVD events (16). The only
study that has examined the asso-
ciation between MHO and CAC
scores found no association (17),
but that study included participants
with hypertension or diabetes mel-
litus in the metabolically-healthy
group and overweight participants
in the comparison group, thus it
did not provide a clear comparison
of MHO with metabolically-
healthy normal-weight individuals.
Therefore, we compared theCAC scores of MHO and metabolically-healthy normal-
weight individuals in a large sample of apparently-healthy
Korean men and women who participated in a health screening
examination program.Methods
Study population. The Kangbuk Samsung Health Study
is a cohort study of South Korean men and women 18
years of age or older who underwent a comprehensive
annual or biennial health examination at the clinics of the
Kangbuk Samsung Hospital Total Healthcare Center in
Seoul and Suwon, South Korea. The study population
consisted of the subset of Kangbuk Samsung Health Study
participants who underwent a cardiac CT to measure CAC
scores as part of a comprehensive health examination from
2010 to 2012 (N ¼ 45,809). CAC scoring has become a
common CVD screening test in Korea (18). More than
80% of participants were employees of various companies
and local governmental organizations and their spouses. In
South Korea, the Industrial Safety and Health Law re-
quires annual or biennial health screening examinations
of all employees, offered free of charge. The remaining
participants were people voluntarily taking screening
examinations.
For this analysis, we excluded participants with a history
of CVD or cancer (n ¼ 1,258) and participants with missing
data for anthropometric measures or other covariates,
including smoking status, alcohol consumption, and physical
activity (n ¼ 3,547), which left a total of 41,205 participants
eligible for the study. We then excluded participants who
had any of the following metabolic abnormalities (7,19):
1) fasting blood glucose 100 mg/dl or current use of blood
glucose–lowering agents (20); 2) blood pressure 130/85
mm Hg or current use of blood pressure–lowering agents(20); 3) triglyceride levels 150 mg/dl or current use of
lipid-lowering agents (20); 4) high-density lipoprotein
cholesterol (HDL-C) <40 mg/dl in men or <50 mg/dl in
women (20); or 5) homeostasis model assessment of insulin
resistance (HOMA-IR) 2.5 (21). The total number of
metabolically-healthy subjects included in the study was
14,828 (Fig. 1).
This study was approved by the Institutional Review
Board of the Kangbuk Samsung Hospital, which exempted
the requirement for informed consent because we only
accessed deidentiﬁed data routinely collected as part of health
screening examinations.
Measurements. Data on medical history, medication use,
family history, physical activity, alcohol intake, smoking
habits, and education level were collected through a self-
administered questionnaire, whereas anthropometry, blood
pressure, and serum biochemical parameters were mea-
sured by trained staff during the health examinations
(22,23). Smoking status was categorized as never, former, or
current smoker. Alcohol consumption was categorized as
none, moderate (20 g/day), or high (>20 g/day). The
weekly frequency of moderate- or vigorous-intensity phys-
ical activity was also assessed. Education level was cate-
gorized as less than college graduate or college graduate
or more.
Height, weight, and body composition were measured by
trained nurses with the participants wearing a lightweight
hospital gown and no shoes. The percentage of body fat
was estimated with a multifrequency bioimpedance analyzer
with 8-point tactile electrodes (InBody 720, Biospace Co.,
Seoul, Korea), which was validated with regard to repro-
ducibility and accuracy for body composition (24). Body mass
index (BMI) was calculated as weight in kilograms divided by
height in meters squared. BMI was classiﬁed according to
Asian-speciﬁc criteria (25): underweight, BMI<18.5 kg/m2;
normal weight, BMI of 18.5 to 23 kg/m2; overweight,
BMI of 23 to 25 kg/m2; and obese, BMI 25 kg/m2. Waist
circumference was measured by trained personnel to the
nearest 0.1 cm at the midpoint between the bottom of the
rib cage and the top of the iliac crest with the subjects
standing, their weight equally distributed on both feet, their
arms at their sides, and head facing straight forward. Waist
circumference was not measured in the Suwon clinic until
2012, so data on waist circumference were restricted to 4,674
participants.
Blood samples were taken from the antecubital vein after at
least a 10-h fast. Serum total cholesterol, triglycerides, and
uric acid were determined with an enzymatic colorimetric
assay. Low-density lipoprotein cholesterol (LDL-C) and
HDL-C were measured directly with a homogeneous enzy-
matic colorimetric assay. Serum high-sensitivity C-reactive
protein (hsCRP) was determined with a particle-enhanced
immunoturbidimetric assay on a Modular Analytics P800
apparatus (Roche Diagnostics, Tokyo, Japan). Serum insulin
was measured with an electrochemiluminescence immuno-
assay on a Modular Analytics E170 apparatus (Roche
Figure 1 Flow Diagram
Flow diagram for the selection of study subjects. CT ¼ computed tomography; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostasis model assessment of insulin resistance.
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2681Diagnostics). Serum glucose was measured by the hexoki-
nase method on a Cobas Integra 800 apparatus (Roche
Diagnostics). Insulin resistance was assessed with the
HOMA-IR according to the following equation: fasting
blood insulin (mU/ml)  fasting serum glucose (mmol/l)/
22.5. The Laboratory Medicine Department at the Kang-
buk Samsung Hospital in Seoul, Korea has been accredited
by the Korean Society of Laboratory Medicine and the
Korean Association of Quality Assurance for Clinical
Laboratories. The laboratory participates in the College
of American Pathologists’ Survey/Proﬁciency Testing
program.
Measurement of CAC by multidetector CT. CT scans
were performed with a LightSpeed VCT XTe-64-slice
multidetector CT scanner (GE Healthcare, Tokyo, Japan)
in both the Seoul and Suwon centers using the same stan-
dard scanning protocol: 2.5-mm thickness, 400-ms rotation
time, 120-kV tube voltage, and 124-mAs (310 mA$0.4 s)
tube current under electrocardiogram-gated dose modula-
tion. CAC scores were calculated as described previously by
Agatston et al. (26). The interobserver and intraobserver
reliability for CAC scores were both excellent (intraclass
correlation coefﬁcient: 0.99) (23). CAC scores were cate-
gorized as 0, 1 to 80, and >80 (27,28).
Statistical analyses. Descriptive statistics were used to
summarize the characteristics of participants by BMI cate-
gories. To test for linear trends, we included the median
value of each BMI category as a continuous variable in the
regression models. We assumed that CAC scores followed
a log-normal distribution with left-censored values at 0
Agatston units (nondetectable CAC scores). To evaluate
the association between BMI categories and CAC, we used
a Tobit regression model for natural log(CAC score þ 1)with Huber-White estimation of standard errors (29,30).
Tobit models were used to estimate ratios and 95% conﬁ-
dence intervals (CIs) of CAC score þ 1 comparing BMI
categories with the normal BMI category. As secondary
analyses, we also estimated prevalence ratios and 95% CIs
for CAC scores of 1 to 80 and >80 for BMI categories
compared with normal BMI using participants with a CAC
score of 0 as the reference group in multinomial logistic
regression models.
Models were adjusted initially for age and sex and then
further adjusted for potential confounding factors, including
education level, smoking status, alcohol intake, and exercise.
We also ﬁtted additional models adjusted for potential in-
termediate variables, including systolic blood pressure, fast-
ing serum glucose, triglycerides, HDL-C, HOMA-IR,
and LDL-C, to evaluate potential mediators of the associ-
ation between obesity and CAC score. Subgroup analyses
to identify interactions between BMI categories and clini-
cally-relevant factors were tested by likelihood ratio tests
that compared models with and without multiplicative
interaction terms. Statistical analyses were performed with
Stata version 11.2 (StataCorp LP, College Station, Texas).
All reported p values are 2-tailed, and comparisons with
p < 0.05 were considered statistically signiﬁcant.
Results
The mean  SD age and BMI of the 14,828 metabolically
healthy participants were 39.3  6.6 years and 23.0  2.7
kg/m2 (BMI range: 14.5 to 39.9 kg/m2), respectively.
Age, fasting glucose, systolic and diastolic blood pressure,
total cholesterol, triglycerides, LDL-C, uric acid, insulin,
HOMA-IR, hsCRP, exercise, and current alcohol use were
Table 1 Baseline Characteristics of Metabolically-Healthy Participants by BMI Category
Overall
BMI Categories, kg/m2
p Value for Trend
Underweight
(<18.5)
Normal Weight
(18.5–22.9)
Overweight
(23.0–24.9)
Obese
(25.0)
Number of participants 14,828 581 6,996 3,997 3,254
Age, yrs 39.3  6.6 37.7  6.6 39.1  6.7 39.7  6.7 39.3  6.5 <0.001
Men 74.2 34.9 63.5 86.2 89.6 <0.001
% Body fat 22.9  5.9 18.6  5.7 21.4  5.8 23.1  5.1 26.7  5.3 <0.001
Current smoker 22.3 16.2 19.6 24.0 27.2 <0.001
Alcohol intake* 17.3 5.3 13.2 20.2 24.5 <0.001
Regular exercisey 14.4 8.4 13.2 15.6 16.4 <0.001
Education levelz 87.5 86.2 86.2 88.3 89.3 <0.001
Systolic BP, mm Hg 109.5  9.8 102.8  10.3 107.5  9.9 111.0  9.1 113.3  8.5 <0.001
Diastolic BP, mm Hg 69.3  7.5 65.5  7.5 67.9  7.6 70.4  7.2 71.9  6.9 <0.001
Waist circumference, cmx 80.7  8.0 67.2  4.0 76.5  5.2 83.9  4.1 90.6  5.5 <0.001
Glucose, mg/dl 90.3  5.8 88.3  6.2 89.9  5.9 90.8  5.7 91.1  5.4 <0.001
Uric acid, mg/dl 5.43  1.32 4.45  1.09 5.11  1.26 5.68  1.24 6.00  1.27 <0.001
Total cholesterol, mg/dl 195.7  32.1 183.4  30.6 191.9  31.8 198.5  31.5 202.6  32.2 <0.001
LDL-C, mg/dl 121.5  30.2 102.3  26.0 115.8  29.2 126.2  29.1 131.5  29.9 <0.001
HDL-C, mg/dl 59.7  12.5 69.6  13.6 62.7  12.7 57.3  11.0 54.5  10.3 <0.001
Triglycerides, mg/dl 84 (64–109) 64 (52–81) 77 (59–99) 90 (70–113) 99 (77–122) <0.001
ALT, U/l 18 (13–25) 13 (10–17) 16 (12–21) 19 (15–27) 24 (18–34) <0.001
GGT, U/l 21 (15–31) 15 (12–20) 18 (13–25) 23 (17–34) 29 (20–43) <0.001
hsCRP, mg/l 0.4 (0.3–0.8) 0.3 (0.2–0.4) 0.3 (0.2–0.6) 0.4 (0.3–0.8) 0.6 (0.4–1.2) <0.001
HOMA-IR 0.88 (0.59–1.25) 0.64 (0.43–0.89) 0.78 (0.53–1.09) 0.91 (0.62–1.27) 1.14 (0.81–1.56) <0.001
CAC score >0 6.8 4.0 5.4 7.5 9.2 <0.001
Values are mean  SD, %, or median (interquartile range), unless otherwise indicated. *Alcohol intake 20 g of ethanol per day. yExercised 3 times per week. zCollege graduate or more. xAmong 4,674
subjects with available waist circumference data (3,438 men, 1,236 women).
ALT ¼ alanine aminotransferase; BMI ¼ body mass index; BP ¼ blood pressure; CAC ¼ coronary artery calciﬁcation; GGT, gamma-glutamyltransferase; HDL-C ¼ high-density lipoprotein cholesterol;
HOMA-IR ¼ homeostasis model assessment of insulin resistance; hsCRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein cholesterol.
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2682positively associated with BMI, whereas HDL-C and cur-
rent smoking were inversely associated with BMI (Table 1).
Of the 14,828 subjects, 859 (5.8%) had a CAC score of 1 to
80 and 144 (1.0%) had a CAC score >80.
In multivariable-adjusted models that accounted for po-
tential confounders, the CAC score ratio comparing MHO
with normal-weight participants was 2.26 (95% CI: 1.48 to
3.43) (Table 2). Similarly, the prevalence ratios comparing
MHO with normal-weight participants were 1.39 (95% CI:
1.15 to 1.67) for CAC score 1 to 80 and 1.67 (95% CI: 1.09
to 2.56 for CAC score >80 (Table 3). Overweight partici-
pants had a modest and not statistically signiﬁcant increase
in the prevalence of coronary calciﬁcation. The CAC score
ratio comparing overweight and normal-weight participantsTable 2 CAC Score Ratios* by BMI Categories in
Underweight
(<18.5)
Normal
(18.5
Number of participants 581 6,9
Age- and sex-adjusted 1.66 (0.55–5.04) Referen
Multivariate-adjusted 1.56 (0.50–4.89) Referen
Values are n or CAC score ratio (95% conﬁdence interval). *Estimated from
outcome. Multivariable model adjusted for age, sex, smoking status, alcoho
Abbreviations as in Table 1.was 1.21 (95% CI: 0.80 to 1.84), whereas the prevalence
ratios comparing overweight and normal-weight participants
were 1.09 (95% CI: 0.91 to 1.31) for a CAC score of 1 to
80 and 1.09 (95% CI: 0.70 to 1.68) for a CAC score >80.
Further adjustment for hsCRP levels did not affect the
results (data not shown).
To explore whether the increased prevalence in coronary
calciﬁcation observed in MHO participants was mediated
by metabolic components associated with obesity, we per-
formed additional analyses adjusted for metabolic risk fac-
tors. Adjustment for fasting blood glucose, systolic blood
pressure, triglyceride levels, HDL-C, and HOMA-IR
slightly reduced the associations, but they remained statis-
tically signiﬁcant (Table 4, model 1). However, after14,828 Metabolically-Healthy Participants
BMI Categories, kg/m2
Weight
–22.9)
Overweight
(23.0–24.9)
Obese
(25.0)
96 3,997 3,254
ce 1.29 (0.86–1.93) 2.52 (1.68–3.78)
ce 1.21 (0.80–1.84) 2.26 (1.48–3.43)
robust Tobit regression models used with natural log(CAC þ 1) as the
l intake, regular exercise, and education level.
Table 3
Prevalence Ratios* for CAC by BMI Categories in 14,828 Metabolically-Healthy
Participants
BMI Categories, kg/m2
Underweight
(<18.5)
Normal Weight
(18.5–22.9)
Overweight
(23.0–24.9)
Obese
(25.0)
Number of participants 581 6,996 3,997 3,254
CAC score 1 to 80
Prevalent cases 19 329 259 252
Age- and sex-adjusted PR* 1.05 (0.64–1.73) Reference 1.11 (0.94–1.33) 1.42 (1.19–1.70)
Multivariate-adjusted PR* 1.03 (0.62–1.72) Reference 1.09 (0.91–1.31) 1.39 (1.15–1.67)
CAC score >80
Prevalent cases 4 50 42 48
Age- and sex-adjusted PR* 1.48 (0.49–4.44) Reference 1.15 (0.75–1.76) 1.91 (1.27–2.89)
Multivariate-adjusted PR* 1.53 (0.50–4.73) Reference 1.09 (0.70–1.68) 1.67 (1.09–2.56)
Values are n or PR (95% conﬁdence interval). *Estimated from multinomial logistic regression models that used CAC scores as outcomes categorized
as 0, 1 to 80, and >80. Multivariable model adjusted for age, sex, smoking status, alcohol intake, regular exercise, and education level.
Abbreviations as in Table 1.
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2683adjustment for LDL-C, the association between MHO and
CAC was markedly attenuated and no longer statistically
signiﬁcant (Table 4, model 2). Similar ﬁndings were evident
in multinomial regression models with categorized CAC
scores as outcomes (data not shown).
The associations between the BMI categories and CAC
scores were similar across participant subgroups (Table 5),
with no signiﬁcant interactions by age (<40 years of age
vs.40 years of age), sex (women vs. men), smoking (current
smoker vs. noncurrent smoker), alcohol intake (<20 g/day
vs. 20 g/day), regular exercise (<3 times/week vs. 3
times/week), hsCRP levels (<1.0 mg/l vs. 1.0 mg/l), and
Framingham risk score (<10% vs. 10%). Even among
participants with Framingham risk score <10%, MHO
participants compared with normal-weight participants had a
signiﬁcantly increased CAC score ratio of 2.20 (95% CI:
1.43 to 3.40).Discussion
In this large study of metabolically-healthy Korean men and
women participating in health screening examinations, we
identiﬁed 2 major ﬁndings. First, MHO participants had a
higher prevalence of subclinical coronary atherosclerosis than
metabolically-healthy normal-weight participants. This as-
sociation was observed in all subgroups that were evaluatedTable 4
Mediation Analysis of the Association Be
in 14,828 Metabolically-Healthy Particip
Underweight
(<18.5)
Norm
(18.
Model 1: CAC score ratio* 1.92 (0.60–6.13) Refere
Model 2: CAC score ratio* 3.01 (0.95–9.55) Refere
Values are CAC score ratio (95% conﬁdence interval). Model 1 adjusted for ag
glucose, systolic blood pressure, triglycerides, high-density lipoprotein cholest
further adjusted for low-density lipoprotein cholesterol. *Estimated from ro
outcome.
Abbreviations as in Table 1.and indicated that MHO is not a harmless condition. Sec-
ond, the association was largely attenuated and no longer
statistically signiﬁcant after adjustment for metabolic risk
factors and LDL-C, even though all participants had
healthy levels of metabolic risk factors. This indicates that
the association between MHO and subclinical atheroscle-
rosis is mediated by metabolic risk factors below levels
considered abnormal, and consequently, the label of meta-
bolically healthy for obese participants is an artifact of the
cutoff levels used and the choice of factors included in the
deﬁnition of metabolic health.
To the best of our knowledge, this is the ﬁrst study to
demonstrate that the MHO phenotype was associated with
subclinical coronary atherosclerosis as measured by CAC
scores. A previous study of the association between MHO
and CAC scores deﬁned metabolically-healthy participants
as those with fewer than 2 metabolic components but
included participants with hypertension or diabetes mellitus
in the metabolically-healthy group (17). Moreover, that
study included overweight participants in the reference
group. Although that study found no association between
MHO and CAC scores, the deﬁnition of the comparison
groups makes these ﬁndings difﬁcult to interpret. In our
study, the large sample size allowed us to select a group of
participants without any metabolic abnormality, as evi-
denced by a low prevalence of CAC scores >0 (6.8%).tween BMI Categories and CAC
ants
BMI Categories, kg/m2
al Weight
5–22.9)
Overweight
(23.0–24.9)
Obese
(25.0)
nce 1.10 (0.72–1.67) 1.84 (1.17–2.91)
nce 0.87 (0.57–1.32) 1.24 (0.79–1.96)
e, sex, smoking status, alcohol intake, regular exercise, education level,
erol, and homeostasis model assessment of insulin resistance. Model 2
bust Tobit regression models used with natural log(CAC þ 1) as the
Table 5 CAC Score Ratios* by BMI Categories in Clinically-Relevant Subgroups of Metabolically-Healthy Participants
Subgroup
BMI Categories (kg/m2)
p Value for
Interaction
Underweight
(<18.5)
Normal Weight
(18.5–22.9)
Overweight
(23.0–24.9)
Obese
(25.0)
Age, yrs 0.57
<40 (n ¼ 7,779) 3.78 (0.61–23.5) Reference 1.55 (0.63–3.85) 2.82 (1.16–6.86)
40 (n ¼ 7,049) 0.92 (0.22–3.78) Reference 1.14 (0.69–1.87) 2.18 (1.30–3.67)
Sex 0.41
Female (n ¼ 3,822) 4.27 (0.57–32.0) Reference 2.52 (0.59–10.8) 1.67 (0.28–10.0)
Male (n ¼ 11,006) 0.83 (0.20–3.41) Reference 1.12 (0.73–1.73) 2.23 (1.45–3.44)
Smoking 0.52
Nonsmoker or ex-smoker (n ¼ 11,520) 1.43 (0.34–5.94) Reference 1.10 (0.66–1.83) 2.57 (1.54–4.28)
Current smoker (n ¼ 3,308) 1.67 (0.24–11.4) Reference 1.48 (0.72–3.06) 1.68 (0.81–3.50)
Alcohol intake 0.86
<20 g/day (n ¼ 12,266) 1.50 (0.45–5.03) Reference 1.11 (0.69–1.78) 2.27 (1.41–3.66)
20 g/day (n ¼ 2,562) 2.05 (0.06–68.3) Reference 1.75 (0.73–4.23) 2.60 (1.10–6.14)
Exercise 0.13
<3 times/week (n ¼ 12,700) 1.34 (0.39–4.62) Reference 1.00 (0.63–1.58) 1.90 (1.19–3.03)
3 times/week (n ¼ 2,128) 4.88 (0.24–98.2) Reference 3.75 (1.40–10.0) 5.96 (2.23–15.9)
High-sensitivity C-reactive protein 0.24
<1.0 mg/l (n ¼ 11,799) 0.95 (0.26–3.47) Reference 1.14 (0.72–1.83) 2.11 (1.29–3.47)
1.0 mg/l (n ¼ 3,029) 16.4 (1.23–218.6) Reference 1.65 (0.66–4.12) 3.00 (1.29–6.97)
Framingham risk score 0.56
<10% (n ¼ 14,718) 1.56 (0.48–5.05) Reference 1.22 (0.79–1.86) 2.20 (1.43–3.40)
10% (n ¼ 109) 0.77 (0.44–1.32) Reference 1.07 (0.76–1.50) 4.97 (3.41–7.25)
Values are CAC score ratio (95% conﬁdence interval). Models were adjusted for age, sex, smoking status, alcohol intake, regular exercise, and education level. *Estimated from robust Tobit regression models
used with natural log(CAC þ 1) as the outcome.
Abbreviations as in Table 1.
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2684Furthermore, in our study, the association between MHO
and CAC scores persisted even among participants with
hsCRP levels<1.0 mg/l and among those with Framingham
risk scores <10%.
Although MHO individuals were protected from CVD in
some studies (5,10), recent longitudinal studies with greater
statistical power have suggested that MHO individuals have
a higher risk of CVD events and death than metabolically-
healthy normal-weight individuals (4,12,19). Previous studies
of MHO and CVD risk, however, assessed only baseline
metabolic status in classifying MHO phenotype and did
not integrate metabolic changes in MHO individuals over
time. This may be important, because the transition to
a metabolically-unhealthy status may affect CVD risk.
Indeed, several studies have shown that the MHO
phenotype may be unstable and progress toward overt
metabolic abnormalities (13,14).
A challenge in evaluating the health implications of the
MHO phenotype is the lack of a universal deﬁnition. In
our study, we deﬁned the metabolically-healthy phenotype
as the absence of any components of the metabolic syndrome
or insulin resistance (7). As a consequence, the prevalence
of the MHO phenotype in our study population was much
lower than in previous studies, which classiﬁed up to 30%
of metabolically-healthy participants among the obese
(31,32). By using a very strict deﬁnition of MHO in a
relatively young population, we were able to provide a very
speciﬁc test of the association between MHO and theprevalence of subclinical coronary atherosclerosis (18). Even
in this apparently healthy population, however, the values of
metabolic parameters increased across BMI categories, and
the MHO phenotype was associated with increased CAC
scores. Furthermore, adjustment for residual metabolic
abnormalities and by LDL-C substantially attenuated the
association, which suggests both that these residual abnor-
malities partly mediate the association between MHO and
CAC and that, even among MHO subjects, obesity may
induce metabolic changes that result in coronary athero-
sclerosis. This ﬁnding provides a cautionary reminder that
the cutoffs for identifying metabolic abnormalities are arbi-
trary and that the association between cardiometabolic risk
factors and CVD risk is continuous, without clear thresholds
(33,34). Also, even though LDL-C is a major risk factor for
CVD, many of the prior studies that addressed the MHO
phenotype did not include LDL-C as a criterion for meta-
bolic health status (7). Thus, the label of “metabolically
healthy” for obese participants can be an artifact of the
choice of factors included and the cutoffs used in the deﬁ-
nition of metabolic health.
In addition to a residual association with traditional
metabolic factors, other mechanisms could explain the as-
sociation between MHO and CAC scores. Adipose tissue is
an active endocrine organ that produces and releases adi-
pokines with a number of proinﬂammatory and other effects
(35). Several adipokines may have direct effects on endo-
thelial function, vascular homeostasis, and atherogenesis
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(36,37) and may be associated with atherosclerosis or
CVD independent of conventional risk factors (30,38,39).
Circulating levels of interleukin-6 and tumor necrosis
factor-alpha, secreted by adipose tissue, may also be involved
in atherogenesis (40,41). Finally, obese subjects may also
have impaired ﬁbrinolysis and increased hypercoagulability
(42). Further mechanistic studies, however, are needed to
understand why the MHO phenotype is associated with
increased prevalence of CAC scores.
Study limitations. First, the cross-sectional design pre-
cludes the determination of causality; however, we studied
asymptomatic, healthy, relatively young individuals free of
clinically-manifest CVD, thereby minimizing the possi-
bility of reverse causation. Second, the deﬁnition of insulin
resistance used in this study was based on HOMA-IR
levels, not on invasive and time-consuming euglycemic
insulin clamp analyses. HOMA-IR and euglycemic insulin
clamp data are strongly correlated (43), but we cannot
discard the possibility that some participants in our study
were insulin resistant. Third, we used BMI as a measure of
obesity, but BMI does not distinguish fat tissue from lean
tissue. If the MHO group had a higher proportion of lean
mass than normal-weight participants, the association be-
tween MHO and the presence of CAC in our study could
be attenuated. Waist circumference measurements, how-
ever, were available only in a fraction of study participants,
which limited our ability to examine the role of fat distri-
bution on CAC scores. Finally, our study was conducted in
asymptomatic, relatively young Korean men and women,
and our ﬁndings cannot be extrapolated to other pop-
ulations. Strengths of our study include the large sample
size; the use of carefully standardized clinical, imaging, and
laboratory procedures; and the availability of carefully
phenotyped participants with no metabolic abnormalities.
Conclusions
The MHO phenotype was associated with an increased
prevalence of subclinical atherosclerosis in a relatively young,
healthy Korean population. These ﬁndings provide strong
support to the hypothesis that MHO is not a harmless
condition. Furthermore, the association between MHO and
CAC scores was mediated in large part by residual levels of
cardiometabolic risk factors, which suggests that the concept
of MHO may be an artifact of the cutoffs used to deﬁne
metabolic abnormalities and of the parameters included in
the deﬁnition of MHO. As a consequence, physicians
should adequately address the increased risk of CVD in
MHO individuals in addition to counseling them about
healthy weight and lifestyle.
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